Body Pharm · research peptides for Spain

The research peptide pens from Body Pharm are multi-dose devices fitted with a dose dial. They cover GLP-1 agonists (tirzepatide, retatrutide), GHRH analogues and recovery peptides (BPC-157, TB-500) in a single order shipped to an address in Spain. Every pen is supplied solely for the purposes of research and in vitro analysis: it is not a medicine and it is not intended for use in people or in animals.

The mechanistic split matters. Retatrutide (Retatrutide) is a triple agonist at the GLP-1, GIP and glucagon receptors; tirzepatide (Tirzepatide) is a dual agonist at the GLP-1 and GIP receptors. The majority of pen shops gloss over that distinction on their product pages. The sections below break down, pen by pen, the mechanism, the steps on the dose dial, the method used to verify the concentration and the 2026 prices in euros, so that you can pin down the exact product you need before you head to checkout.

Key points

• Multi-dose pens remove the reconstitution error, the dead-volume loss and the syringe measurement drift that come with the vial-and-syringe workflow.
• Retatrutide (triple agonist: GLP-1/GIP/glucagon) and tirzepatide (dual agonist: GLP-1/GIP) are not interchangeable in dose: the receptor coverage of the two is different.
• Ten products cover five research areas: weight loss (the GLP-1 axis), muscle growth (growth hormone secretagogues), recovery (BPC-157, TB-500), longevity (NAD+, MOTS-c, GHK-Cu) and skin (melanotan II, GHK-Cu).
• Every pen arrives with its concentration verified by HPLC and is aseptically packed in type 1 borosilicate glass cartridges. Shipping to Spain costs €15 per order and delivery takes between 3 and 5 working days.
• Each product has its own dosing protocol written up in the guide index. Start with the retatrutide, semaglutide and tirzepatide comparison before you settle on an active compound.

What Body Pharm's research peptide pens are

Multi-dose pens take the biggest sources of variability in peptide research off the table: reconstitution error, dead-volume loss and syringe measurement drift. Every pen ships to addresses anywhere in Spain at a single flat rate of €15, with delivery usually taking 3–5 working days, and it is supplied strictly for the purposes of research and in vitro analysis.

Reconstitution error ranks among the largest sources of variability in any protocol that works with peptides. The volume of bacteriostatic water, the material carried over in the vial and the dead space of the syringe all shift the mass that is actually delivered per unit. A sealed, pre-filled pen with a dose dial graduated in milligrams does away with those variables: 0.25 mg dialled on a Monday is 0.25 mg dialled three weeks later, from the same batch. It also cuts down on peptide waste, because nothing is being drawn from a residual volume that degrades after repeated punctures of the septum.

The concentration of every Body Pharm product is verified by high-performance liquid chromatography (HPLC), the same analytical method that pharmaceutical-grade peptide suppliers apply in 2026. The outer packaging arrives plain and unbranded, for discreet receipt at home addresses or at laboratory addresses alike.

For the comparative pharmacology to read before you pick a product, see retatrutide, semaglutide and tirzepatide compared. To calibrate the dose dial against the published protocols, read how to dose retatrutide. If you are still weighing up the two formats, the pen or vial guide sets the two workflows side by side.

Full range: every pen available in 2026

Body Pharm's 2026 range in Spain brings together ten products across five research categories: agonists of the GLP-1, GIP and glucagon receptors for metabolic work; GHRH analogues and growth hormone secretagogues for the somatotropic axis; recovery peptides; and skin and longevity peptides. Every pen is filled and sealed to an EU laboratory standard, with its concentration verified by HPLC. The full catalogue is on the peptides page and the combinations with a discount for quantity are under packs.

Read the mechanism column first. Retatrutide is a triple agonist at the GLP-1, GIP and glucagon receptors; tirzepatide is a dual agonist at GLP-1 and GIP only. The glucagon arm shifts hepatic lipid handling and energy expenditure in a way that dual agonism does not reproduce, and that is why the two compounds are not interchangeable in dose in comparative studies. Semaglutide, a single-axis agonist, and CagriSema, which adds an amylin analogue, appear on this page and in the guides as reference compounds: they are not part of the Spanish catalogue. Choosing a pen on the basis of category alone loses these distinctions.

Price per milligram: how to check it yourself

The price of a pen says little until the amount of active compound appears next to it. That is why it pays to divide the price in euros by the number of milligrams in the pen. At catalogue prices: the Retatrutide 32 pen costs €249, which is to say roughly €7.78 per milligram; the Retatrutide 64 pen costs €379, which is to say roughly €5.92 per milligram. Anyone who works with the same active compound over an extended period pays less per milligram with the larger pen.

The same calculation can be applied to any offer, provided that the supplier states the amount of active compound. If that figure is missing, no comparison is possible, and that is exactly what we record in the comparisons. The prices currently in force are always on the product page; the figures in this text are a snapshot.

GLP-1 pens for weight-loss research

Pens on the GLP-1 axis differ from one another in their receptor coverage, not just in potency. Retatrutide acts on the GLP-1, GIP and glucagon receptors. Tirzepatide acts on GLP-1 and GIP only. As comparative reference points: semaglutide is a single-axis GLP-1 receptor agonist and CagriSema pairs a GLP-1 agonist (semaglutide) with an amylin analogue (cagrilintide). Choosing by milligrams collapses four distinct pharmacologies into a single purchasing decision, which is why the mechanism column in the table carries more weight than the dose figure does.

Retatrutide: triple agonism (GLP-1 + GIP + glucagon)

The glucagon receptor arm is what sets retatrutide apart. Glucagon co-agonism is associated with an increase in hepatic lipid oxidation and with a measurable rise in resting energy expenditure that dual agonists do not reproduce at equivalent doses. For anyone comparing protocols, that means retatrutide results at a given GLP-1-equivalent dose cannot be predicted from tirzepatide data, nor the other way round. The 32 mg and 64 mg pens cover, respectively, the low-titration window and the steady-state window. The protocol detail is in how to dose retatrutide; the compound profile is in what retatrutide is, and the head-to-head comparison in retatrutide, semaglutide and tirzepatide.

Tirzepatide: dual agonism (GLP-1 + GIP)

Tirzepatide is a dual agonist at the GIP and GLP-1 receptors, with no activity at the glucagon receptor. GIP co-agonism modulates adipocyte handling and appears to soften the gastrointestinal tolerance ceiling that is seen with pure GLP-1 monotherapy, so that its titration curves differ from those of semaglutide in the published comparisons. The Tirzepatide 60 pen covers extended research blocks without any need to place a repeat order. The protocol is in how to dose tirzepatide and the compound profile in what tirzepatide is.

CagriSema: GLP-1 plus an amylin analogue

CagriSema is the only compound in this group that touches a non-incretin axis, and it is treated here as a reference: it is not part of the Spanish catalogue. Cagrilintide is a long-acting amylin analogue that acts on the amylin and calcitonin receptors; it slows gastric emptying and modulates satiety through a pathway that runs parallel to, and is not redundant with, the GLP-1 agonism of semaglutide. That design means CagriSema is not mechanistically substitutable for tirzepatide or for retatrutide, even though the weight-change endpoints overlap in the literature. The reference protocol is in how to dose CagriSema.

Semaglutide: single-axis GLP-1 receptor agonist

Semaglutide is the GLP-1 receptor agonist against which the triple- and dual-agonism pens are compared. It is not part of the Spanish catalogue either: we keep it as a reference compound because almost all of the titration literature was built on it. Its profile is in what semaglutide is and its titration schedule in how to dose semaglutide.

Growth hormone axis pens: GHRH and secretagogues

Pens on the growth hormone axis fall into two mechanistic classes. Secretagogues drive endogenous release from the pituitary: tesamorelin and CJC-1295 + ipamorelin, both of them in the Spanish catalogue and in the muscle growth category. Recombinant somatropin (HGH) makes up the other class, because it bypasses the pituitary and acts directly on GH receptors; it is not sold in this shop and it appears here only by way of mechanistic contrast, with its profile in what somatropin (HGH) is and its reference protocol in how to dose somatropin (HGH). The choice between one class and the other depends on whether the protocol needs a stimulated pulsatile profile or a direct exogenous load.

Tesamorelin 32 mg: stabilised GHRH analogue

Tesamorelin (Tesamorelin) is a synthetic analogue of GHRH(1–44) with a trans-3-hexenoyl modification at the N-terminus that resists cleavage by dipeptidyl peptidase IV (DPP-IV) and extends its half-life relative to native GHRH. It binds to pituitary GHRH receptors to stimulate the endogenous release of growth hormone while preserving the somatostatin feedback loop, which is why supraphysiological spikes in GH are uncommon in the protocol data. The Tesamorelin 32 pen covers the standard daily dosing arms without having to place a repeat order halfway through a study. The compound profile is in what tesamorelin is and the protocol in how to dose tesamorelin.

CJC-1295 + ipamorelin 20 mg: GHRH plus a selective secretagogue

This pen brings two complementary mechanisms together in a single cartridge, with the two peptides co-dissolved at 50% and a single dial whose number is the dose of each one. CJC-1295 (the DAC form in this formulation) is a GHRH analogue that raises the amplitude of the growth hormone pulse through the GHRH receptor, with a signal that extends over a period of days and a single daily administration, in the evening. Ipamorelin is a selective ghrelin/GHS-R1a agonist that triggers an additional pulse with no measurable effect on cortisol, prolactin or adrenocorticotropic hormone (ACTH), which is what sets it apart from older secretagogues such as GHRP-6. The synergy is additive at the pituitary: GHRH primes the somatotroph and the ghrelin mimetic fires it. The compound profile is in what CJC-1295 + ipamorelin is; the detail is in CJC-1295 vs. ipamorelin and in how to dose CJC-1295 + ipamorelin; the pen itself is CJC-1295 + Ipamorelin 20.

Recovery and skin pens: BPC-157, TB-500 and more

The recovery and skin arms of the Body Pharm range cover BPC-157, TB-500, melanotan II, GHK-Cu, NAD+ and MOTS-c. The two most requested recovery compounds, BPC-157 and TB-500, are supplied together in a single combined pen, with a joint protocol. The full set is in the recovery and skin categories.

BPC-157 and TB-500

BPC-157 (Body Protection Compound) is a fifteen-amino-acid pentadecapeptide derived from a protein found in gastric juice. TB-500 is a synthetic fragment of thymosin beta-4. The two are not interchangeable. BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) and modulates the nitric oxide system at the local site of the injury; TB-500 sequesters G-actin and promotes cell migration systemically. That is why they are researched in combination rather than one being swapped for the other, and why the BPC-157 + TB-500 pen carries both of them. The contrast between the mechanisms is in the BPC-157 vs. TB-500 guide, the split-dose schedule in how to dose BPC-157 and TB-500 and the joint profile in what BPC-157 + TB-500 is.

Melanotan II 20 mg

Melanotan II is a non-selective agonist of the melanocortin receptors, with activity at MC1R, MC3R, MC4R and MC5R. Its action on MC1R drives eumelanin synthesis in melanocytes, which is the basis of its use in research on pigmentation; its activity on MC4R produces the side effects on appetite and libido documented in the early clinical work. The Melanotan II 20 pen is suited to dose-escalation studies in which the steps below one milligram matter. The compound profile is in what melanotan II is and the protocol in how to dose melanotan II.

GHK-Cu, NAD+ and MOTS-c

GHK-Cu is a copper-binding tripeptide (glycyl-L-histidyl-L-lysine) used in research on the dermal matrix and on fibroblasts: collagen synthesis, decorin expression and wound-bed signalling rather than systemic endpoints; its profile is in what GHK-Cu is and the protocol in how to dose GHK-Cu. NAD+ is supplied for research into cellular energetics and the sirtuin pathway, with its profile in what NAD+ is and its protocol in how to dose NAD+. MOTS-c is a sixteen-amino-acid mitochondrial peptide studied in the context of metabolic regulation and insulin sensitivity; its profile is in what MOTS-c is and its protocol in how to dose MOTS-c.

Why the multi-dose pen matters in research

The multi-dose pen format replaces manual preparation with a pre-filled, sealed 3 ml cartridge and a dial that sets the dose directly in milligrams and is validated at the factory. That single design decision removes three main sources of error from the vial-and-syringe workflow: reconstitution variability (bacteriostatic water ratios worked out by eye), the measurement drift of an insulin syringe below 0.25 mg and the repeated septum punctures that compromise sterility over the course of a study lasting several weeks.

A protocol run from a 1 ml vial typically loses between 8 and 12% of the declared contents to the dead volume in the hub and the needle. A sealed multi-dose pen reduces that loss to the residue that remains below the last dialable dose. For dose-escalation work, consult how to dose retatrutide. For the receptor criterion that decides which GLP-1 to use, the retatrutide, semaglutide and tirzepatide comparison covers the split between dual and triple agonism. The full contrast between the formats is in pen or vial.

How we validate quality

Every Body Pharm pen is filled, sealed and dose-validated to an EU laboratory standard. In practice, that comes down to four measurable control points:

1. Concentration verification by HPLC on every batch, in line with the analytical assay standards that pharmaceutical-grade peptide suppliers apply in 2026.
2. Aseptic filling and sealing in type 1 borosilicate glass cartridges, with cold-chain handling from filling right through to dispatch.
3. Dialled-dose accuracy control, so that 0.25 mg on the dial delivers 0.25 mg across the whole cartridge, not just in the first third of it.
4. Identity confirmation against reference standards before the batch is released, with a retention sample kept for the shelf life of the cartridge.

The peptides are supplied solely for the purposes of scientific research and in vitro analysis. The pen format does not change that classification. What it changes is the floor of precision that a researcher is able to work from.

How to read a certificate of analysis

A Body Pharm certificate of analysis (CoA) states the active compound, the batch number and the purity value determined by HPLC. Three things matter when you read it:

1. The batch number must match the one on your pen. A certificate applies to a batch, not to a product. Compare the number on the label with the number on the document.
2. The purity value states what HPLC measures. It describes the proportion of the target peptide in the sample. Properties that do not appear on the certificate cannot be inferred from it.
3. Combined pens must list both components. For BPC-157 + TB-500 and for CJC-1295 + Ipamorelin, check that the document records both of the active compounds.

All of the certificates are collected in the certificates of analysis listing and linked from every product page. If you are missing the certificate for a particular batch number, write to us through the contact page and we will send you the document.

Ordering, shipping and discretion: what to expect

We ship only to addresses in Spain. There is a single shipping option: €15 per order, with delivery usually in 3–5 working days in 2026, regardless of the number of pens in the order. There is no express shipping and no free-shipping threshold. Payment is made by card. At the moment of dispatch you receive the tracking code for your order by email.

The outer packaging is plain and unbranded. It carries no product name, no reference to the peptide and no Body Pharm logo on the outside. Inside, the pen sits in its original sealed pharmaceutical packaging, with the batch and concentration labelling intact, so that traceability for your records is preserved without compromising discretion at the door. The full conditions are set out on the shipping page, and the conditions for returns are under returns and in the terms and conditions.

What is in the box, and what is not

Every shipment contains the sealed pen, the insert with the batch documentation and a printed handling note. The outer label carries only your delivery address and the shipment code. Nothing on the outside identifies the contents, the sector of the sender or the value of the parcel.

All products are supplied strictly for the purposes of scientific, analytical and laboratory research and are not fit for human consumption. If you are still deciding which compound to order, the retatrutide, semaglutide and tirzepatide comparison and the how to dose retatrutide protocol cover the two questions that come up most often before checkout.

Research categories: shop by objective

If you already know the endpoint and want to compare compounds within it, browse by research objective. The pen catalogue is divided into five categories, each with its own page and its own mechanism notes.

Weight loss covers the GLP-1 axis: retatrutide (triple GLP-1/GIP/glucagon agonist) and tirzepatide (dual GLP-1/GIP agonist), on the weight loss page. Still undecided? The retatrutide, semaglutide and tirzepatide comparison is the quickest read, and how to dose retatrutide answers the question that comes next.

Muscle growth groups the combined CJC-1295 + ipamorelin pen and tesamorelin on the muscle growth page. Recovery covers BPC-157 and TB-500 in a single combined pen, on the recovery page. Longevity brings together NAD+, MOTS-c and GHK-Cu in the longevity category. Skin lists melanotan II and GHK-Cu on the skin page.

For the mechanism-level deep dives on all of the pens above, the guide index is the single point of entry, and the comparisons set each pen against the equivalent offering from other brands. All of the pens are supplied solely for the purposes of research and analysis.

Dosing protocols and research guides

Every pen in the catalogue has its protocol written up in the guide index, with titration schedules, doses as dialled on the pen and mechanism notes. Treat these guides as the methodological layer behind each product, not as sales copy. All of the protocols are written for in vitro research.

The GLP-1 set covers four titrations: how to dose retatrutide, how to dose tirzepatide, how to dose semaglutide and how to dose CagriSema; the last two describe reference compounds that are not in the Spanish catalogue. For the receptor-level differences before you commit to one of them, the retatrutide, semaglutide and tirzepatide comparison is the reading to do beforehand.

The protocols on the growth hormone axis form a group of their own: CJC-1295 + ipamorelin, tesamorelin and, as a reference, somatropin (HGH). Recovery is covered by the BPC-157 + TB-500 protocol, which in this shop runs from a single combined pen.

Skin and longevity round off the library: melanotan II, NAD+, MOTS-c and GHK-Cu. Bookmark the index before you place your order.